KR970706816A - 알츠하이머 질환에서의 아밀로이드 베타A4형성을 감소시키는 〔R-(Z)〕-알파-(메톡시이미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴의 용도(Use of 〔R-(Z)〕-Alpha-(Methoxyimino)-Alpha-(1-Azabicyclo)〔2. 2. 2〕Oct-3-YI)Acetonitrile to Reduce Amyloid Beta A4 Formation in Alzheimer's Disease) - Google Patents

알츠하이머 질환에서의 아밀로이드 베타A4형성을 감소시키는 〔R-(Z)〕-알파-(메톡시이미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴의 용도(Use of 〔R-(Z)〕-Alpha-(Methoxyimino)-Alpha-(1-Azabicyclo)〔2. 2. 2〕Oct-3-YI)Acetonitrile to Reduce Amyloid Beta A4 Formation in Alzheimer's Disease)

Info

Publication number
KR970706816A
KR970706816A KR1019970702700A KR19970702700A KR970706816A KR 970706816 A KR970706816 A KR 970706816A KR 1019970702700 A KR1019970702700 A KR 1019970702700A KR 19970702700 A KR19970702700 A KR 19970702700A KR 970706816 A KR970706816 A KR 970706816A
Authority
KR
South Korea
Prior art keywords
alpha
disease
alzheimer
acetonitrile
oct
Prior art date
Application number
KR1019970702700A
Other languages
English (en)
Other versions
KR100393365B1 (ko
Inventor
로저 에드워드 마크웰
쥴리에 호킨스
캐롤 웬디 그레이
Original Assignee
데이비드 로버츠
스미스클라인 비참 피. 엘. 씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데이비드 로버츠, 스미스클라인 비참 피. 엘. 씨. filed Critical 데이비드 로버츠
Publication of KR970706816A publication Critical patent/KR970706816A/ko
Application granted granted Critical
Publication of KR100393365B1 publication Critical patent/KR100393365B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

알츠하이머 질환을 앓고 있는, 또한 발생할 위험이 있는 환자에게서 비아밀로이드성 경로를 따르는 아밀로이드 전구체 단백질의 프로세싱을 촉진하는 방법, 및 효과적이고, 비독성인 양의 아세토니트릴 화합물을 알츠하이머 질환을 앓고 있는, 또는 발생할 위험이 있는 환자에게 투여하여 βA4 생성을 감소시킴으로써 알츠하이머 질환의 예방 또는 치료 방법, 그리고 방법에 사용되는 의약의 제조에서의 그 화합물의 용도 및 그 방법에 사용되는 조성물.

Description

알츠하이머 질환에서의 아밀로이드 베타A4형성을 감소시키는 〔R-(Z)〕-알파-(메톡시이미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴의 용도(Use of 〔R-(Z)〕-Alapha-(Methoxyimino)-Alpha-(1-Azabicyclo)〔2, 2, 2〕Oct-3-YI)Acetonitrile to Reduce Amyloid Beta A4 Formation in Alzheimer's Disease)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 알츠하이머 질환을 앓고 있는 또는 발생할 위험이 있는 환자에게서 비아밀로이드성 경로를 따르는 아밀로이드 전구체 단백질 프로세싱을 촉진하기 위한 의약의 제조에 있어서의 〔R-(Z)〕-알파-(메톡시아미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴 또는 제약상 허용되는 그의 염의 용도.
  2. βA4 생성을 감소시킴으로써 알츠하이머 질환의 치료 또는 예방에 사용되는 〔R-(Z)〕-알파-(메톡시이미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴 또는 제약상 허용되는 그의 염의 용도.
  3. 비독성 유효량의 〔R-(Z)〕-알파-(메톡시이미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴 또는 제약상 허용되는 그의 염을 투여하는 것을 포함하는, 알츠하이머 질환을 앓고 있는, 또는 발생할 위험이 있는 환자에게서 비아밀로이드성 경로를 따르는 아밀로이드 전구체 단백질 프로세싱을 촉진하기 위한 방법.
  4. 비독성 유효량의 〔R-(Z)〕-알파-(메톡시이미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴 또는 제약상 허용되는 그의 염을 투여하는 것을 포함하는, 알츠하이머 질환을 잃고 있는 또는 발생할 위험이 있는 환자에게서 βA4 생성을 감소시킴으로써 알츠하이머 질환을 치료 또는 예방하는 방법.
  5. 알츠하이머 질환을 앓고 있는 또는 발생할 위험이 있는 환자에게서 비아밀로이드성 경로를 따르는 아밀로이드 전구체 단백질 프로세싱을 촉진하기 위하여 사용되는, 〔R-(Z)〕-알파-(메톡시이미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴 또는 제약상 허용되는 그의 염 및 제약상 허용되는 담체를 포함하는 제약 조성물.
  6. βA4 생성을 감소시킴으로써 알츠하이머 질환의 치료 및(또는) 예방에 사용되는 〔R-(Z)〕-알파-(메톡시이미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴 또는 제약상 허용되는 그의 염 및 제약상 허용되는 담체를 포함하는 제약 조성물.
  7. 제1항 내지 제6항 중 어느 한 항에 있어서, 제약상 허용되는 염이 모노히드로클로라이드인 용도, 방법 또는 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970702700A 1994-10-25 1995-10-17 알츠하이머질환에서의아밀로이드베타a4형성을감소시키는[r-(z)]-알파-(메톡시이미노)-알파-(1-아자비시클로-[2.2.2]옥트-3-일)아세토니트릴의용도 KR100393365B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9421472A GB9421472D0 (en) 1994-10-25 1994-10-25 Novel methods
GB9421472.3 1994-10-25

Publications (2)

Publication Number Publication Date
KR970706816A true KR970706816A (ko) 1997-12-01
KR100393365B1 KR100393365B1 (ko) 2003-12-18

Family

ID=10763350

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970702700A KR100393365B1 (ko) 1994-10-25 1995-10-17 알츠하이머질환에서의아밀로이드베타a4형성을감소시키는[r-(z)]-알파-(메톡시이미노)-알파-(1-아자비시클로-[2.2.2]옥트-3-일)아세토니트릴의용도

Country Status (22)

Country Link
US (1) US5891887A (ko)
EP (1) EP0786998B1 (ko)
JP (1) JPH10509697A (ko)
KR (1) KR100393365B1 (ko)
CN (1) CN1085529C (ko)
AT (1) ATE214926T1 (ko)
AU (1) AU698695B2 (ko)
BG (1) BG101500A (ko)
BR (1) BR9509433A (ko)
CZ (1) CZ287370B6 (ko)
DE (1) DE69526102T2 (ko)
DK (1) DK0786998T3 (ko)
ES (1) ES2173977T3 (ko)
GB (1) GB9421472D0 (ko)
HK (1) HK1002057A1 (ko)
HU (1) HUT77007A (ko)
NO (1) NO312055B1 (ko)
NZ (1) NZ295155A (ko)
PT (1) PT786998E (ko)
SK (1) SK50497A3 (ko)
WO (1) WO1996012486A1 (ko)
ZA (1) ZA958946B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751607B2 (en) * 1995-07-29 2002-08-22 Smithkline Beecham Plc Method of treatment of dementia
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
CN1292696A (zh) * 1998-03-11 2001-04-25 史密丝克莱恩比彻姆有限公司 组合物
GB9815383D0 (en) * 1998-07-15 1998-09-16 Smithkline Beecham Plc Novel method of treatment
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US7816149B2 (en) * 2004-03-29 2010-10-19 Applied Photonics Worldwide, Inc. Nanobioprocessor for protein and cell therapy
GB0428170D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Mono and Combination Therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69034146T2 (de) * 1989-04-13 2005-07-14 Beecham Group P.L.C., Brentford Chemische Verbindungen
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
JPH0725786A (ja) * 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
MX9300875A (es) * 1992-02-20 1993-08-31 Smithkline Beecham Plc Procedimiento para la preparacion de compuestos azabiciclicos.
WO1994009370A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors
GB9409705D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
CZ287370B6 (en) 2000-11-15
HK1002057A1 (en) 1998-07-31
CN1085529C (zh) 2002-05-29
EP0786998A1 (en) 1997-08-06
NO312055B1 (no) 2002-03-11
CZ125197A3 (en) 1997-07-16
CN1170365A (zh) 1998-01-14
SK50497A3 (en) 1997-09-10
DE69526102T2 (de) 2002-10-31
ATE214926T1 (de) 2002-04-15
ES2173977T3 (es) 2002-11-01
EP0786998B1 (en) 2002-03-27
AU698695B2 (en) 1998-11-05
KR100393365B1 (ko) 2003-12-18
NZ295155A (en) 2000-07-28
HUT77007A (hu) 1998-03-02
DK0786998T3 (da) 2002-07-15
NO971899L (no) 1997-04-24
WO1996012486A1 (en) 1996-05-02
MX9703077A (es) 1997-07-31
DE69526102D1 (de) 2002-05-02
GB9421472D0 (en) 1994-12-07
PT786998E (pt) 2002-09-30
BG101500A (en) 1998-01-30
JPH10509697A (ja) 1998-09-22
NO971899D0 (no) 1997-04-24
BR9509433A (pt) 1997-09-16
ZA958946B (en) 1996-08-20
US5891887A (en) 1999-04-06
AU3843195A (en) 1996-05-15

Similar Documents

Publication Publication Date Title
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BR0110420A (pt) Agonistas muscarìnicos
ZA938421B (en) Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders
CA2427227A1 (en) Lactam compound
CZ176595A3 (en) The application of anticonvulsive agents for the preparation of medicaments intended for treating parkinson's disease and parkinson's syndromes
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
DE69401577D1 (de) Verabreichung von lamotrigin zur behandlung von neuro-aids
BG105302A (en) Means for improving cognition
KR970706816A (ko) 알츠하이머 질환에서의 아밀로이드 베타A4형성을 감소시키는 〔R-(Z)〕-알파-(메톡시이미노)-알파-(1-아자비시클로-〔2. 2. 2〕옥트-3-일)아세토니트릴의 용도(Use of 〔R-(Z)〕-Alpha-(Methoxyimino)-Alpha-(1-Azabicyclo)〔2. 2. 2〕Oct-3-YI)Acetonitrile to Reduce Amyloid Beta A4 Formation in Alzheimer's Disease)
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
NZ320355A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6- tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
BR0211855A (pt) Medicamento e método para tratamento e melhoria da qualidade restauradora do sono
RU2003127718A (ru) Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости
BR0009080A (pt) Método de tratamento da apnéia do sono
KR890003378A (ko) 혐기성균에 대해 항균작용을 갖는 나프티리딘 화합물
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
HUP0103149A2 (hu) Gyógyszerkészítmény Alzheimer-kór kezelésére
BR9913242A (pt) Uso de r(+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-p iperidinametanol para o tratamento de desordens de sono
KR890001558A (ko) 공황(恐慌) 장애를 경감시키는 제피론 및 이의 약학적 허용 산부가염
KR930007452A (ko) 벤조디아제핀-금단 환자의 불안증 치료방법
ATE339199T1 (de) Methoden zur kolikenbehandlung

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee